Abstract: This invention provides a method for modifying plant growth and development comprising expressing an isolated nucleic acid sequence encoding Cdc25 or a homologue, analogue or derivative thereof in one or more plant cells, tissues or organs operably under the control of a regulatable promoter that does not confer expression throughout the plant under all conditions.

Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.

Abstract: Cis-2,6-disubstituted piperdine analogs, or lobeline analogs, having the general formula: 1

Abstract: Pharmaceutical compounds comprising bridged nicotine analogs of N-octylnicotinium iodide (NONI) having selective antagonist properties at &agr;3&bgr;2-containing nicotinic receptor subtypes, and compositions containing these compounds. The compounds and compositions are used to treat central nervous system pathologies.

Abstract: Cis-2,6-disubstituted piperdine analogs, or lobeline analogs, having the general formula: are used to treat diseases of the central nervous system, drug abuse and withdrawal therefrom as well as to treating eating disorders.

Abstract: Pharmaceutical compounds comprising bridged nicotine analogs of N-octylnicotinium iodide (NONI) having selective antagonist properties at &agr;3&bgr;2-containing nicotinic receptor subtypes, and compositions containing these compounds. The compounds and compositions are used to treat central nervous system pathologies.

Abstract: 3-O-Acetylmorphine-6-sulfate analogues are potent, centrally-acting morphine derivatives. The compounds are useful for the treatment of pain.

Abstract: Pharmaceutical preparations containing of agmatine, congeners, analogs or derivatives thereof for use in preventing or treating epilepsy, seizures and other electroconvulsive disorders are provided. Embodiments include administering an effective amount of agmatine, an agmatine analog or a pharmaceutically acceptable salt thereof to a human subject in need of treatment or prevention of epilepsy, seizure or other electroconvulsive disorder to treat, reduce, or prevent the disorder in the subject.

Abstract: Nigella sativa derivatives, thymoquinone (TM) and dithymoquinone (DIM) are used in treatment of parental and multi-drug resistant human cancers.

Abstract: A radiator valve for preventing water from leaking out of a radiator when the radiator is detached from its hot water supply. The radiator valve includes a tubular housing with a lumen and opposite first and second ends. A ball valve is rotatably mounted in the lumen of the tubular housing to substantially block passage of fluid through the lumen of the tubular housing. The first end of the tubular housing is designed for attachment to a fluid opening of a radiator to fluidly connect the lumen of the tubular housing to the fluid housing of the radiator. The second end of the tubular housing is designed for removable attachment to a fluid supply outlet of a fluid supply conduit to fluidly connect the lumen of the housing to the fluid supply conduit.

Abstract: The present invention is directed to a method for controlling plant cell growth comprising modulating the level and or catalytic activity of a cell cycle control protein in a plant cell for a time and under conditions sufficient to control cell division. Preferably, the cell cycle control protein is p34.sup.cdc2 or p34.sup.cdc2 -like molecule having a cyclin related kinase function and the plant is a monocotyledonous plant or dicotyledonous plant. The present invention is also directed to other cell cycle control proteins, so termed since they function similarly to p34.sup.cdc2 or control p34.sup.cdc2 activity. Such proteins include p13.sup.suc1, cyclin, cdc25, and the products of nim1, wee1 and mik-1 or combinations thereof, separately, or together with p34.sup.cdc2.

Abstract: Lobeline and nicotine evoke [.sup.3 H]overflow from rat striatal slices preloaded with [.sup.3 H]dopamine ([.sup.3 H]DA). The lobeline-evoked overflow is calcium-independent and not antagonized by mecamylamine, suggesting a mechanism of action other than the stimulation of nicotinic receptors. Whereas nicotine stimulates nicotinic receptors, lobeline inhibits [.sup.3 H]DA uptake into synaptic vesicles and striatal synaptosomes. The results suggest that different mechanisms are responsible for the increase in striatal DA release evoked by lobeline and nicotine. [.sup.3 H]-Dihydrotetrabenazine [.sup.3 H]DTBZ), used routinely to probe a high-affinity binding site-on the vesicular monoamine transporter (VMAT2) binds to vesicle membranes from rat striatum. Lobeline inhibits [.sup.3 H]DTBZ binding with an IC.sub.50 of 0.90 .mu.M, consistent with its IC.sub.50 of 0.88 .mu.M for inhibition of [.sup.3 H]DA uptake into vesicles.

Abstract: This invention relates to canvanine analogs, their pharmaceutical compositions, and a method for treatment of cancer, particularly pancreatic cancer.

Abstract: Methods are disclosed that suggest the use of lobeline and analogs thereof in treating individuals for drug dependence and withdrawal and for eating disorders.

Abstract: Optically active nornicotine compounds as a treatment for dopamine-related conditions and disease states. Such disease states include the treatment of myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, eating disorders, ulcers, drug addiction and as a substitute for psycho-stimulant self-administration.

Abstract: The present invention is directed to a method for controlling plant cell growth comprising modulating the level and or catalytic activity of a cell cycle control protein in said plant cell for a time and under conditions sufficient to control cell division. Preferably, the cell cycle control protein is p3.sup.4cdc2 or like molecule and the plant is a monocotyledonous plant or dicotyledonous plant.

Abstract: Nicotine analogs that have nicotinic receptor antagonist properties. These compounds have been shown to competitively inhibit dopamine release induced by nicotine. The nicotine analog compounds are useful in the treatment of nicotine abuse, smoking cessation therapy, as an antidote for nicotine intoxication, treatment of cognitive disorders such as Alzheimer's disease and for the treatment of Parkinson's disease.

Abstract: Prodrugs containing an active drug molecule linked to a polyethylene glycol group, and a method of use thereof are described. Exemplary soluble ester prodrugs contain naproxen, triamcinolone acetonide, gancyclovir, taxol, cyclosporin, dideoxyinosine, trihydroxy steroids, and flurbiprofen molecules linked to polyethylene glycol (PEG) groups. Pharmaceutical compositions containing these prodrugs, and a method of using these esters for treating disease states or symptoms are also described.

Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.

Abstract: The present invention provides for the preparation and use of ribo- and deoxyribo-nucleosides and polynucleotide analogs. The polynucleotide analogs are made of polynucleosides which contain sulfonate and sulfonamide linkages.